FUJIFILM Cellular Dynamics’ New iPSC Manufacturing Facility in Wisconsin, Quadrupling iPSC Research and Services
The site will also serve as the company's new headquarters, expanding its services in iPSC-based drug discovery, regenerative medicine, and cell therapy work.
Key Points
- FUJIFILM Cellular Dynamics has opened a new iPSC development and manufacturing facility in Madison that will also serve as the company’s headquarters.
- The company says the 175,000-square-foot site will quadruple capacity for its iPSC-based research products and services and add room for future cell therapy manufacturing.
- The facility is part of Fujifilm’s previously announced $200 million U.S. investment to expand research products and cell therapy manufacturing capabilities.
FUJIFILM Cellular Dynamics has opened a new induced pluripotent stem cell (iPSC) development and manufacturing facility in Madison, expanding its capacity to produce iPSC products and services for drug discovery, regenerative medicine, and cell therapy work. The site will also serve as the company’s new headquarters.
The new facility is expected to quadruple its manufacturing footprint for iPSC-based research products and services. It will also expand production of iCell, its iPSC-derived cell lines, which are being used for targeted drug discovery. Here are a handful of examples from the lineup:
The 175,000-square-foot building includes cell culture manufacturing labs, process development labs, and a center of excellence for gene editing. The expansion comes as interest and regulations are steering away from animal testing in both the USA and Europe, for both ethical and accuracy reasons. iPSC-derived differentiated cells could be a more effective option to model human biology.
The company did a great presentation at the Cell & Gene Meeting on the Mesa a few months ago about their iPSC CDMO services:
https://www.youtube.com/watch?v=TMkH_e0bUNY
Want to keep up on regenerative medicine? Get the weekly newsletter here.
